Jump to content

Rinucumab

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Edgar181 (talk | contribs) at 20:05, 14 November 2019 (autocalc. to fix units). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Rinucumab
Monoclonal antibody
Type?
SourceHuman
Targetplatelet-derived growth factor receptor beta
Clinical data
Other namesREGN2176
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6472H9974N1710O2022S38
Molar mass145309.21 g·mol−1

Rinucumab (REGN2176) is a monoclonal antibody designed for the treatment of neovascular age-related macular degeneration.[1]

This drug was developed by Regeneron Pharmaceuticals, Inc.

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Rinucumab, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Rinucumab&oldid=926192147"